key: cord-0711843-95sj346p authors: Bhuiyan, Farhana Rumzum; Howlader, Sabbir; Raihan, Topu; Hasan, Mahmudul title: Plants Metabolites: Possibility of Natural Therapeutics Against the COVID-19 Pandemic date: 2020-08-07 journal: Front Med (Lausanne) DOI: 10.3389/fmed.2020.00444 sha: 5926ff6ceae7653f1e77427c097fb42a96b1e70d doc_id: 711843 cord_uid: 95sj346p COVID-19, a disease induced by SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2), has been the cause of a worldwide pandemic. Though extensive research works have been reported in recent days on the development of effective therapeutics against this global health crisis, there is still no approved therapy against SARS-CoV-2. In the present study, plant-synthesized secondary metabolites (PSMs) have been prioritized to make a review focusing on the efficacy of plant-originated therapeutics for the treatment of COVID-19. Plant metabolites are a source of countless medicinal compounds, while the diversity of multidimensional chemical structures has made them superior to treat serious diseases. Some have already been reported as promising alternative medicines and lead compounds for drug repurposing and discovery. The versatility of secondary metabolites may provide novel antibiotics to tackle MDR (Multi-Drug Resistant) microbes too. This review attempted to find out plant metabolites that have the therapeutic potential to treat a wide range of viral pathogens. The study includes the search of remedies belonging to plant families, susceptible viral candidates, antiviral assays, and the mode of therapeutic action; this attempt resulted in the collection of an enormous number of natural therapeutics that might be suggested for the treatment of COVID-19. About 219 plants from 83 families were found to have antiviral activity. Among them, 149 plants from 71 families were screened for the identification of the major plant secondary metabolites (PSMs) that might be effective for this pandemic. Our investigation revealed that the proposed plant metabolites can serve as potential anti- SARS-CoV-2 lead molecules for further optimization and drug development processes to combat COVID-19 and future pandemics caused by viruses. This review will stimulate further analysis by the scientific community and boost antiviral plant-based research followed by novel drug designing. COVID-19, a disease induced by SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2), has been the cause of a worldwide pandemic. Though extensive research works have been reported in recent days on the development of effective therapeutics against this global health crisis, there is still no approved therapy against SARS-CoV-2. In the present study, plant-synthesized secondary metabolites (PSMs) have been prioritized to make a review focusing on the efficacy of plant-originated therapeutics for the treatment of COVID-19. Plant metabolites are a source of countless medicinal compounds, while the diversity of multidimensional chemical structures has made them superior to treat serious diseases. Some have already been reported as promising alternative medicines and lead compounds for drug repurposing and discovery. The versatility of secondary metabolites may provide novel antibiotics to tackle MDR (Multi-Drug Resistant) microbes too. This review attempted to find out plant metabolites that have the therapeutic potential to treat a wide range of viral pathogens. The study includes the search of remedies belonging to plant families, susceptible viral candidates, antiviral assays, and the mode of therapeutic action; this attempt resulted in the collection of an enormous number of natural therapeutics that might be suggested for the treatment of COVID-19. About 219 plants from 83 families were found to have antiviral activity. Among them, 149 plants from 71 families were screened for the identification of the major plant secondary metabolites (PSMs) that might be effective for this pandemic. Our investigation revealed that the proposed plant metabolites can serve as potential anti-SARS-CoV-2 lead molecules for further optimization and drug development processes to combat COVID-19 and future pandemics caused by viruses. This review will stimulate further analysis by the scientific community and boost antiviral plant-based research followed by novel drug designing. Coronaviruses comprise a group of large, enveloped, positivesensed, single-stranded RNA viruses that damage the respiratory tract of mammals including humans, bats, and other animals, leading to infections in the respiratory tract (1) (2) (3) (4) (5) . The Coronavirus disease 2019 (COVID-19), initially called 2019 novel coronavirus (2019-nCoV), is an agile respiratory disease caused by a novel coronavirus primarily detected in Wuhan, China (6, 7) . Now, it has spread to 216 countries and caused the death of more than 0.5 million people worldwide and was declared as a pandemic by the World Health Organization (WHO) (8, 9) . Seven types of human coronaviruses have been reported so far, including HCoV-OC43, HCoV-229E, HCoV-HKU1, HCoV-NL63, severe acute respiratory syndrome (SARS)-CoV, Middle East respiratory syndrome (MERS-CoV), and 2019novel coronavirus nCoV (10) . Among them, MERS-CoV, SARS-CoV, and nCoV have taken the concern of scientists worldwide. In 2003, the severe acute respiratory syndrome (SARS) outbreak occurred in Guangdong (southern China) (6, 11) which infected 8,000 people and resulted in 800 deaths in 26 countries. Only a decade later, another coronavirus has attacked the world and caused another devastating outbreak, MERS, which infected 2,494 people and caused the deaths of 858 worldwide (12, 13) . However, the COVID-19 pandemic caused by SARS CoV-2 resulted in remarkable levels of morbidity and mortality all over the world. Initially China, followed by the USA, Italy, France, Iran, Spain, Russia, Turkey, and the UK became hotspots for SARS CoV-2. The virus hotspot has now moved to Latin America and, at this time, Brazil, Mexico, and Peru are the new hotspots of SARS CoV-2. The important aspects of the pathobiology, a viral response phase, and a hyperbolic host response phase are linked with the morbidity and mortality in COVID-19 patients (14) . However, the increased cytokine levels (IL-6, IL-10, and TNF-α), lymphopenia (in CD4+ and CD8+ T cells), and decreased IFNγ expression in CD4+ T cells are the more risky and possibly life-threatening events related to severe COVID-19 (15) (16) (17) . The infection rate of COVID-19 is increasing gradually but scientists have not been able to suggest any specific drug, vaccine, or any other certified therapeutic agents against SARS-CoV-2, which consequently leads to the significant morbidity and mortality. On the other hand, plants have been essential to human welfare for their uses as therapeutics since ancient times (18, 19) . According to the WHO, about 80% of the world's population depends on medicinal plants or herbs to fulfill their medicinal needs (20-22). A significant amount of antiviral compounds produced from numerous kinds of plants have been used in many studies (23) (24) (25) . Researchers all around the world are screening therapeutic drugs from existing antiviral plant secondary metabolites (PSMs) and are also trying to find novel compounds from medicinal plants [(26-159) ; Supplementary Table 1 ] to avert this global crisis. Plant metabolites can halt the activity of enzymes involved in the replication cycle of CoVs including papain-like protease and 3CL protease, halt the fusion of the S protein of coronaviruses and ACE2 of the host, and also inhibit cellular signaling pathways (123, 144, 160) . Screening from existing PSMs, researchers have been trying to find novel compounds from medicinal plants to prevent numerous diseases, including COVID-19 (Supplementary Table 1) . Therefore, the current manuscript aims to describe potential metabolites from plant sources that have antiviral properties that might be aligned for the alternative approach against COVID-19. Hence, understanding the structure, life cycle, pathogenicity, cell signaling, epidemiology of the recently emerging virus, drug targets, and drug discovery process have become very important issues to find specific/effective therapeutics. In December 2019, SARS CoV-2, one of the most devastating viral outbreaks since SARS CoV and MERS, originated from Wuhan city seafood market in China (161) (162) (163) . The virus was found to be transmitted through close contact with infected people or through exposure to coughing, sneezing, and respiratory droplets (164, 165) . It has already been reported to have spread to 216 countries and caused more than 0.5 million deaths. Brazil is now the new hotspot for SARS CoV-2 after the USA, Russia, France, Italy, Germany, Spain, and the UK, where more than 11 million people are infected (166, 167) . The pleomorphic or spherical shaped SARS COV-2 has a single-stranded RNA genome of 26.4-31.7 kb in length and a crown-like glycoproteins on its surface (168) (169) (170) (171) (172) (173) . It is more similar to SARS CoV (over 80%) than MERS (174, 175) . However, the RNA genome of CoV-2 is considered as one of the largest genomes compared to those of other RNA viruses (176, 177) . The largest open reading frame, ORF1ab, encodes non-structural proteins while the remaining ORFs encode four structural proteins, namely the envelope glycoprotein or spike protein (S), envelope (E) protein, membrane (M) protein, and nucleocapsid (N) protein. The S protein mediates attachment to the host cell while the E protein is involved in virus assembly, membrane permeability of the host cell, and virus-host cell interaction. The M protein is known as a central organizer for the coronavirus assembly and the nucleocapsid (N) protein is usually involved in the processing of helical ribonucleocapsid complex, including some accessory proteins (172, 178) . Six types of mutations are found in the genome of SARS CoV-2 while three mutations have been reported in orf 1ab gene, two mutation in S gene, and the final one in the orf 7b and orf 8 (174, 175) . Proteomic analysis revealed that SARS CoV-2 is vastly homologous to SARS CoV but two proteins, orf 8 and orf 10, are not homologous to SARS CoV (175) . To complete its life cycle, SARS CoV-2 passes into the human body through the nose, mouth, or eyes and then attaches itself to the receptor-binding domain (RBD) using the surface glycoprotein (Spike-protein) of the virion which tries to attach with the hACE2 receptor (179, 180) . The entry mechanism of SARS CoV-2 depends on cellular transmembrane serine protease 2 (TMPRSS2) and furin, along with viral receptor ACE2 (180) (181) (182) . However, after the fusion of the SARS CoV-2 virion particle with the host cell membrane, the envelope and capsid part of the virus are removed. The virus releases its genetic material (RNA) into the host cell cytoplasm and acts as mRNA for the translation from ORF1a and ORF1ab to produce pp1a and pp1ab polypeptides (169, 183) . Subsequently, chymotrypsin-like protease (3CL pro ) slices these polypeptides into 16 non-structural proteins (NSPs) that are responsible for replication and transcription (184) . Then, infected cells produce proteins when they become hijacked by SARS CoV-2. In this situation, the immune system supports the assembly of SARS CoV-2 into new copies of virion particles (185, 186) . Freshly synthesized viral nucleic acids and proteins then assemble into the lumen of the ERGIC (Endoplasmic Reticulum Golgi Intermediate Compartment) and leave the cells through exocytosis [(187, 188) ; Figure 1 ]. Infected cells release virions and infect other human cells. SARS-CoV-2 viral infection can be divided into three stages: the asymptomatic period, non-severe symptomatic period, and the severe infection stage (17, 189). SARS CoV-2 patients are reported to have a significant amount of cytokines and chemokines; the levels of cytokines are especially highly increased in patients admitted to ICUs (Intensive Care Unit) (190, 191) . These significantly high levels are what results in a patient reaching a critical stage. However, the main mediator of SARS CoV-2, the spike glycoprotein, is found in two conformations (192) and the enzyme 3CL pro of SARS-CoV-2 share a 99.02% sequence identity with 3CL pro of SARS-CoV, which is also highly similar to bat SARS CoV 3CL pro (193) . SARS CoV-2 binds to the host cell receptor with a higher affinity than SARS CoV (194) . SARS CoV-2 has shown some strategic alteration with the substrate-binding site of bat SARS CoV-2 and 12 pointmutations are found in SARS CoV-2 compared to SARS CoV. Mutations disrupt the significant hydrogen bonds and modify the receptor binding site (RBS) of SARS-CoV-2 3CL pro . However, the Frontiers in Medicine | www.frontiersin.org occurrence of recurrent mutations can lead to new strains with alterations in virulence, which one of the reasons discovering a suitable vaccine to combat SARS CoV-2 is challenging (175, 195) . A fundamental therapeutic approach to treat multi-viral infections is the interruption of human host-virus interactions (17). The major structural proteins of SARS CoV-2 can be obvious targets for drugs designed against COVID-19. In addition, 16 non-structural proteins (NSPs) can also be considered (169) . However, the manifestation of recurrent recombination events is a major hindrance to develop SARS CoV-2 specific vaccines/drugs (176) . Up-to-date studies revealed that, though SARS-CoV-2 and SARS-CoV identify a similar receptor (ACE2) in humans (194, 196) , there is a noteworthy variation in the antigenicity between SARS-CoV and SARS-CoV-2 which has significance on the development of therapeutic options against this rapidly emerging virus (197) . The SARS-CoV-2 spike protein exhibits a higher affinity to the ACE2 receptor in comparison to SARS-CoV, but hACE2 showed a lower binding affinity to RBD (Receptor Binding Domain) of SARS COV-2 when compared to SARS CoV (194, 198) . The two most paramount enzymes of SARS CoV-2, proprotein convertase furin-potentiates cell fusion and serine protease TMPRSS2, are responsible for S-protein activation and are propitious drug targets for the treatment of COVID (180, 194, 199) . Though extensive research works are being continued for the development of effective vaccines or drug compounds against SARS-CoV-2, efficacious therapeutics have not yet been attained (200) . Moreover, interferon therapies, monoclonal antibodies, oligonucleotide-based therapies, peptides, small-molecule drugs, and vaccines, are regarded as some strategic approaches for controlling or preventing COVID-19 (201, 202) . Existing drugs can be used as the first-line treatment for coronavirus outbreaks, but this is not the ultimate solution to eradicate the disease (203) . Therefore, the development of therapeutic drugs for the treatment of the COVID-19 outbreak have gathered considerable attention. Scientists from different fields are trying to figure out the way to develop therapeutics. However, experimental implications of drug recombination might be both expensive and time-consuming, whereas computational evaluation may bring about testable hypotheses for systematic drug recombination (174) . Though there are approved, repurposed drugs currently in clinical use, there is still an urgent need for specific antiviral therapeutics and vaccines (199) . Bioengineered and vectored antibodies and therapies based on cytokines and nucleic acid which target virus gene expression have been found as promising to treat coronavirus infections (204) . For example, the repurposing drugs, including favipiravir, remdesivir, lopinavir, ritonavir, nebulized α-interferon, chloroquine, hydroxychloroquine, ribavirin, and interferon (IFN), have been shown to be effective for the treatment of COVID-19. Apart from this, some therapeutics are in clinical trials, such as peptide vaccine (mRNA-1273) (198) and antibody therapies (205) . Recently, plasma therapy showed promising results for COVID-19 treatment (206, 207) . But, application of these synthetic drugs are not efficient as they exhibit adverse direct or indirect side effects [(208-220); Table 1 ]. In addition, scientists Teicoplanin Maculopapular or erythematous rash and drug-related fever Rubitecan - Frontiers in Medicine | www.frontiersin.org all around the world are trying to find out some prominent drug and multi-epitope vaccine candidates against this deadly virus using various kinds of immuno-informatics approaches (221, 222) . Therefore, the urgent need for safe, effective, and inexpensive therapies/drugs with negligible side effects against COVID-19 is imperative. PSMs are a source of natural antiviral compounds that could be an effective option, as most of them are safer and more cost-effective compared to orthodox drugs (223) , though some PSMs are toxic too. The dependency on and popularity of plant-based drugs are increasing day by day (224) . Due to the presence of multiple compounds in crude plant extracts, it can be either beneficial or not, depending on the amounts used each time; if properly regulated, better activity might be shown. It was also found that crude extracts can target multiple sites at a time in a virion particle (225) . However, this is yet to be tested against SARS-CoV-2. PSMs can affect the disruption of cell membrane functions and structures (226) , interference with intermediary metabolisms (227) , interruption of DNA/RNA synthesis and function (228) , interruption of normal cell communication (quorum sensing) (229) , and the induction of coagulation of cytoplasmic constituents (230) . Different kinds of plant metabolites act against SARS CoV (Supplementary Table 1 ). Plant-based products affect several key events in the pathogenic process. For example, curcumin is effective for its antineoplastic, anti-proliferative, anti-aging, antiinflammatory, anti-angiogenic, antiviral and anti-oxidant effects, and can regulate redox status, protein kinases, transcription factors, adhesion molecules, and cytokines in the human body (231) . In silico analysis revealed that anti-SARS CoV PSMs could be one of the most valuable drug targets against SARS CoV-2 [(232-261); Table 2 ]. A huge amount of plant metabolites have remained unexplored due to the extensive process of isolation of the target compound. Now, various types of modern techniques have been developed for the isolation of lead compounds from crude extracts including maceration, percolation, decoction, reflux extraction, soxhlet extraction, pressurized liquid extraction, supercritical fluid extraction, ultrasound assisted extraction, microwave-assisted extraction, pulsed electric field extraction, enzyme assisted extraction, hydro distillation, and steam distillation (179) . These techniques can lead us to find out novel anti-SARS CoV-2 compounds earlier than traditional techniques. In addition, plant metabolomics are used as a tool for the discovery of novel drugs from plant resources (262, 263) . Plants produce diversified low molecular weight PSMs to protect them from different herbivores and microbes (264) . Before the discovery of allopathic drugs, these leading natural sources were extensively used for treating several kinds of human diseases (265, 266) . Due to the increased resistance of microbial pathogens against allopathic drugs, researchers have now returned to natural resources, focusing especially on plant metabolites, to find out lead compounds to fight against human pathogens (175) . Moreover, about 35% of the global medicine market (which accounts for 1.1 trillion US dollars) have been shared by medicinal products prepared using natural plants or herbs (265) . Investigations are undergoing for the finding of novel and modern drugs from numerous herbal preparations to fight against this microbial resistance war. Many similarities have been found between SARS CoV and SARS CoV-2 (both of them belong to beta family, containing the same genetic material-RNA, and using the same receptor for viral attachment-ACE2, with an 86% identity and 96% similarity of genome, with almost the same pathogenesis). Thus, previously reported antiviral plant metabolites for SARS CoV can be considered as emerging drug candidates for COVID-19. Right now, the setbacks arising from viral infection around the world have placed budget constraints on researchers trying to discover effective antiviral drugs. However, some PSMs have already shown anti-SARS CoV activity where other antiviral activities are also reported (Supplementary Table 1 ). These results suggest that there is a scope to find alternative medicines and specific compounds. So, plants could be a vital resource in the fight against COVID-19. Our study suggests that around 76 natural metabolites from different plant species can be efficiently active against COVID-19 ( Table 3 and Supplementary Figure 1 ). Table 1 ). First and foremost are polyphenols, which contain multiple phenolic rings, and are classified as phenols, flavonoids, lignans, hydroxycinnamic acid, stilbenes, and hydroxybenzoic acid (267) . We found polyphenols in numerous plants ( Table 4 ) which exerted antiviral activity (269-271) against a wide range of viruses including HIV-1, HIV-2, HSV-1, HSV-2, Influenza virus, Dengue virus, HBV, HCV, Infectious bronchitis virus (IBV), Murbarg virus, Ebola virus, Newcastle disease virus (NDV), Poliomyelitis-1 virus, Lentivirus, and Coronavirus. Polyphenols work against coronaviruses using diverse mechanisms including actuating or inhibiting cellular signaling pathways or halting papain-like protease (PL pro ) and 3-chymotripsin-like protease (3CL pro ) enzyme (269, 272) . Some polyphenol compounds (30-(3-methylbut-2enyl)-30, 4-hydroxyisolonchocarpin, broussochalcone A, 4,7trihydroxyflavane, broussochalcone B, papyriflavonol A, kazinol A, kazinol B, kazinol F, kazinol J, and broussoflavan A) isolated from Broussonetia papyrifera showed promising activity against SARS CoV. Higher efficiency against PL pro as observed by these compounds though activity against M pro or 3CL pro is not up to the mark. Specially, papyriflavonol A possesses impressive activity against SARS CoV (IC 50 3.7, l M) (272) . In silico analysis revealed that polyphenols can inhibit SARS CoV-2 Mpro and RdRp effectively (273, 274) . In our study, we have Alkaloids are another class of natural organic compounds which are classified into several groups based on their heterocyclic ring, such as tropanes, pyrrolidines, isoquinoline purines, imidazoles, quinolizidines, indoles, piperidines, and pyrrolizidines (278) . Alkaloids are very promising against HIV-1, HSV-1, HSV-2, DNV, VSV, Influenza virus, and Newcastle disease virus (NDV) ( Table 4 ). Different kinds of alkaloids showed anti-SARS activity including emetine, Ipecac, Macetaxime, tylophorine, and 7-methoxy cryptopleurine, through the inhibition of protease enzyme, RNA synthesis, and protein synthesis (244, 279) . In addition, some alkaloids act against SARS CoV as a nucleic acid intercalating agent such as tetrandrine, fangchinoline, cepharanthine, and lycorine through degrading nucleic acids and inhibiting spike and nucleocapsid proteins (280) . Virtual screening analysis revealed that 10-Hydroxyusambarensine and Cryptoquindoline-two alkaloid compound isolated from African medicinal plants showed anti-SARS CoV and anti-SARS CoV-2 activity through inhibition of their M pro (256) . Chloroquine, a derivative of alkaloid, is found to be active against anti-SARS CoV-2 (281). So, some PSMs as alkaloids can be alternative drug targets for COVID-19 (280) . Another class of PSMs, saponins (amphipathic glycosides), are found ubiquitously in plants which showed antiviral activities against Newcastle disease virus (NDV), Simian (SA-11) virus, Murine norovirus (MNV) and Feline calicivirus (FCV), RSV, VSV, HSV-1,HSv-2, HIV-1, Epstein-Barr virus (EBV), (SA-11) and human (HCR3) rotaviruses, Influenza virus, and Dengue virus ( Table 4) . Plants produce five carbon isoprene derived terpenes which are the largest and most diverse group of PSM. They are classified by monoterpenes, diterpenes, triterpenes, sesterterpenes, hemi terpenes, and sesquiterpenes (282). They exhibited antiviral activity against Bovine viral diarrhea virus, HSV-1, Poliovirus type 2 (PV-2) and vesicular stomatitis virus (VSV), Dengue virus serotype-1 (DENV-1), Influenza A and B viruses, HIV-1, HIV-2, SIV mac 251, and SARS-CoV ( Table 4 ). Ten diterpenes, two sesquiterpenes, and two triterpenes showed anti-SARS activity with IC 50 of 3-10 µM (283) . In silico analysis also revealed that terpene Ginkgolide A can strongly inhibit SARS CoV-2 protease enzyme (284) . Carbohydrates, mainly classified as monosaccharides, disaccharides, polysaccharides, and oligosaccharides (282), are found as antiviral agent against Human rotavirus, Influenza A virus, HSV-1, HSV-2, Herpes simplex virus (HSV), RSV, Coxsackie B3 Virus, and VSV [(285); Table 4 ]. Acyclovir is an FDA (Food and Drug Administration) approved antiviral drug which is obtained from Carissa edulis (Supplementary Table 1 ). It is mainly used for herpes simplex virus, chickenpox, and shingles. The group basis structure of some major compounds can be found in Table 5 . Drug discovery from plant metabolites refers to the extraction and purification of active ingredients from conventional cures. Natural plant products comprise complicated chemical structures which differ according to their numerous species. There are several classes of PSMs which are responsible for the biological activities of herbal medicines. PSMs exert their actions on molecular targets that differ from one case to the other. These targets may be enzymes, mediators, transcription factors, or even nucleic acids (286) . Good knowledge of the chemical composition of plants leads to a better understanding of their possible and specific medicinal value. Drug discovery and development have become a wide interdisciplinary field over recent decades and many factors are involved in the successful evolution from a bioactive compound into a potential drug [(287, 288); Figure 2 ]. When existing methods with advanced technologies are applied, it can lead to a modern revelation of drugs, benefitting medicinal purposes (223, 289) . The development of modern technologies has streamlined the screening of natural products in discovering new drugs. Research for drug discovery must create robust and prudent lead molecules, which is progressed from a screening hit to a drug candidate through structural elucidation and structure recognizable proof available from high throughput technology like GC-MS, NMR, IR, HPLC, and HPTLC. Utilizing these advanced technologies gives us an opportunity to perform research in screening novel molecules employing a computer program and database to set up common items as a major source for drug discovery. It finally leads to lead structure discovery. Powerful new technologies are revolutionizing natural herbal drug discovery (223) . Steps associated with the drug discovery process from natural resources is illustrated (Figure 3) . However, several factors involving the conversion of a desirable compound into a valuable drug candidate include availability, bioavailability, intellectual property, and the strong pharmacokinetic profile of the compound (268, 290) . Sometimes researchers find great bioactivity of a plant-derived compound in in vitro analysis but unfortunately, the desired compound becomes ineffectual under in vivo conditions (291) . In vivo is a very crucial step to move to animal trials or subsequent clinical trials. Even if the compound shows promising activity in in vivo assay but it can still become ineffective in animal model trials due to a poor pharmacokinetic profile (292) . Under in vivo condition, the target compound remains in direct contact with cells, while in animal models the compound moves to various stages where it might lose its bioactivity (292) . For example, despite curcumin having promising antioxidant, anticancer, anti-inflammatory, and antimicrobial activities, it has not been released as a drug yet due to its poor bioavailability (292) . Another propitious drug candidate, epigallocatechin gallate (EGCG), showed antioxidant, antihypertensive, anticancer, antimicrobial, and anti-inflammatory activity (293, 294) but unfortunately, it has also failed to obtain drug designation due to the same reason mentioned for curcumin (292) . To remedy these problems, researchers around the world are working to develop new approaches. Changing the administration route might increase the bioavailability of a compound. For example, the bioavailability of an antiinflammatory compound, andrographolide, is increased when it is administered intravenously instead of through oral administration (295) . Other methods to enhance the bioavailability of target compound include using drug delivery systems, the nano-formulation of a drug, using adjuvant systems, or altering structural analogs (208, 296) . Furthermore, the modification of pharmacokinetic profiles of compounds like absorption, distribution, metabolism, and excretion can escalate its probability as drug candidate (268) . Indeed, there is an urgent need for specific protocols for invention of novel bioactive compounds and for this purpose it is very crucial for related organizations, companies, and agencies, including the World Health Organization (WHO), Food and Drug Administration (FDA), European Medicines Agency (EMA), World Trade Organization (WTO), International Conference on Harmonization (ICH), World Intellectual Property Organization (WIPO), biotech companies, pharmaceutical pharmaceuticals companies, and several other companies and agencies, to work together. However, plant-originated therapeutics need to be taken under consideration against SARS-CoV-2 as they have already shown promising hopes for different critical conditions caused by deadly pathogens. The seven major drug targets of SARS CoV-2 were described before (176) . Similarly, screening of PSMs for drug establishment by molecular docking is efficient in terms of time and cost. Even the development of vaccines through computational biology was found to be effective for previous severe viruses like MERS using animal models, target antigens, and probable vaccine candidates (181) . But still, there exists a lack of a complete review for PSMs as alternative drug therapeutics. Our review aims at establishing PSMs as a strong and safe candidate for the treatment of SARS CoV-2. Through suggesting probable antiviral plant metabolites or screening, druggability analysis of plant metabolites against SARS-CoV-2 has become a time-saving practice (280, 297) . Without establishing a drug development pipeline that includes clinical trials, these suggested candidate PSMs will end up only in journal publications or be shelved as herbal formulations on a supermarket store as a traditional medicine and will never be a modern drug. Undoubtedly, the plant an underutilized source of novel bioactive compounds and is one of the hotspots to fight against this microbial resistance war. The decrypting of PSMs is not increasing so much in comparison to the number of metabolites produced from plants. A biotechnological approach can offer a desired amount of secondary metabolites in a rapid and eco-friendly way against SARS-CoV-2 (298) . In addition, plant metabolomics are now used as a tool for discovery of novel drugs from plant resources (299) . Characterization of genes and proteins involved in secondary metabolic pathways are also very crucial to understand. Therefore, omics approaches (transcriptomics, proteomics, and metabolomics) have paramount importance in food research and drug discovery (300, 301) for human welfare. Genetic modifications for engineering plant metabolites can be helpful for reaching a specific drug. Quality control of natural products is also very important. So, laboratory support, skilled manpower, and funding is also very important for drug discovery from natural resources. Scientists all around the world are trying to discover the most effective antiviral drug to combat SARS CoV-2. In this situation, our study accentuated some plant secondary metabolites that showed prominent antiviral activity against Table 2 ; (179, 220, 222, 297) ]. Plants are a dramatically underutilized source of bioactive compounds with a broad spectrum of antiviral activities. Some Chinese traditional plant formulations have been reported as being anti-SARS CoV-2 and this formulation is also provided in COVID patients (302, 303) . We reported here on 219 plants which act against a wide range of DNA/RNA viruses, but the plant PSMs that showed promising activity against SARS CoV and MERS might be a desired drug candidate against SARS CoV-2. So, this review gathered all antiviral plants in a single platform to facilitate laboratory-based research for the development of novel drug/molecular therapeutics to overcome this and future pandemic situations. The world is facing a serious health crisis, and it needs an effective solution to combat the burning flame of COVID-19. Researchers are trying to find an effective way to overcome this situation, and the present study could help them to think with a new dimension by using the knowledge from the databases based on the plant metabolites (304, 305) . Finally, advanced and rapid acting extraction, purification, and characterization techniques used for plant metabolites as well as multidisciplinary expertise and funding are very essential for novel drug discovery. Articles were selected and identified by searching specific keywords and journal citations for each section of a manuscript. Related peer reviewed scientific journal articles were screened from different journal depositories after reviewing abstracts and original data. The authors initiated this project to facilitate the research on molecular therapeutics from plant sources as an immediate action in response to the COVID-19 pandemic situation. FB and MH designed the project. FB prepared the first draft. FB, SH, TR, and MH have investigated the data and completed the manuscript. All authors have read through the manuscript and approved it for submission and publication. We are thankful to Mr. Md. Fayezur Rahman (MSS in Economics, Comilla University) for drawing the figures as authors expected. Our sincere gratitude to Mr. Mohammad Saifullah (MA in English, University of Chittagong) for proofreading of the manuscript. We are grateful to the editors and reviewers for their valuable comments during the review process to improve the manuscript. The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed. 2020.00444/full#supplementary-material Coronavirus genome structure and replication Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding Coronavirus avian infectious bronchitis virus Pathogenicity of turkey coronavirus in turkeys and chickens Coronaviruses: an overview of their replication and pathogenesis Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor Infants born to mothers with a new coronavirus (COVID-19). Front Pediatr Director-General's Opening Remarks at the Media Briefing on COVID-19 Director-General's Opening Remarks at the Media Briefing on COVID-19 Chest CT findings in 2019 novel coronavirus (2019-nCoV) infections from Wuhan, China: Key points for the radiologist Coronaviruses-drug discovery and therapeutic options Global surveillance, national surveillance, and SARS Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: present and future COVID-19: a new virus, but a familiar receptor and cytokine release syndrome Phytochemistry and pharmaceutical evaluation of Balanites aegyptiaca : an overview Epimedium koreanum Nakai water extract exhibits antiviral activity against porcine epidermic diarrhea virus in vitro and in vivo Diarylheptanoids from Alnus japonica inhibit papain-like protease of severe acute respiratory syndrome coronavirus Anti-influenza diarylheptanoids from the bark of Alnus japonica Anti-SARS coronavirus 3C-like protease effects of Isatis indigotica root and plant-derived phenolic compounds Isocorilagin, isolated from Canarium album (Lour.) Raeusch, as a potent neuraminidase inhibitor against influenza A virus Inhibition of HIV-1 reverse transcriptase, toxicological and chemical profile of Calophyllum brasiliense extracts from Chiapas Anti-H5N1 virus flavonoids from Capparis sinaica Veill Chemical constituents of Capparis sinaica Veill. plant and its antimicrobial effects A protein with antiproliferative, antifungal and HIV-1 reverse transcriptase inhibitory activities from caper (Capparis spinosa) seeds Isolation, structural modification, and HIV inhibition of pentacyclic lupanetype triterpenoids from Cassine xylocarpa and Maytenus cuzcoina Orally administered Salacia reticulata extract reduces h1n1 influenza clinical symptoms in murine lung tissues putatively due to enhanced natural killer cell activity Potent in vitro antiviral activity of Cistus incanus extract against HIV and Filoviruses targets viral envelope proteins In-vitro antiviral activity of Solanum nigrum against Hepatitis C Virus Phytomedicine Ellagitannins from Tuberaria lignosa as entry inhibitors of HIV Activities of aqueous ethanolic extracts from Combretum adenogonium Steud. Ex A. Rich (Combretaceae) Phytochemical and antifungal studies on Terminalia mollis and Terminalia brachystemma Chemical composition and anti-herpes simplex virus type 1 (HSV-1) activity of extracts from Cornus canadensis An extract from Taxodium distichum targets hemagglutinin-and neuraminidase-related activities of influenza virus in vitro Bioactivity-guided isolation of anti-hepatitis B virus active sesquiterpenoids from the traditional Chinese medicine : Rhizomes of Cyperus rotundus Phytochemical characterization and evaluation of the antimicrobial, antiproliferative and pro-apoptotic potential of Ephedra alata Decne. hydroalcoholic extract against the MCF-7 breast cancer cell line Extracts of Equisetum giganteum L and Copaifera reticulate Ducke show strong antiviral activity against the sexually transmitted pathogen herpes simplex virus type 2 Triterpenes and steroids from Euphorbia denticulata Lam. with anti-herpes symplex virus activity Antiviral activities of extracts of Euphorbia hirta L. against HIV-1, HIV-2 and SIVmac251 Carolignans from the aerial parts of Euphorbia sikkimensis and their anti-HIV activity Antiinfluenza virus activity of extracts from the stems of Jatropha multifida Linn. Collected in Myanmar Evaluation of antiviral activity of Ocimum sanctum and Acacia arabica leaves extracts against H9N2 virus using embryonated chicken egg model Antiviral activity of peanut (Arachis hypogaea L.) skin extract against human influenza viruses An evaluation of the inhibitory effects against rotavirus infection of edible plant extracts Breaking down the barriers to a natural antiviral agent: antiviral activity and molecular docking of Erythrina speciosa extract, fractions, and the major compound The traditional use of Vachellia nilotica for sexually transmitted diseases is substantiated by the antiviral activity of its bark extract against sexually transmitted viruses Extracts from Acacia catechu suppress HIV-1 replication by inhibiting the activities of the viral protease and Tat Anti -herpes simplex virus type-1 activity and phenolic content of crude ethanol extract and four corresponding fractions of Quercus brantii L Acorn Antiviral activity of Quercus persica L.: high efficacy and low toxicity Antiviral activity of ethanol extract of Geranii Herba and its components against influenza viruses via neuraminidase inhibition The root extract of the medicinal plant Pelargonium sidoides is a potent HIV-1 attachment inhibitor Investigation of the influence of EPs R 7630, a herbal drug preparation from Pelargonium sidoides, on replication of a broad panel of respiratory viruses Antiviral activity of Ladania067, an extract from wild black currant leaves against influenza a virus in vitro and in vivo Tannins from Hamamelis virginiana bark extract: characterization and improvement of the antiviral efficacy against influenza, a virus and human papillomavirus Antiviral and antiphlogistic activities of Hamamelis virginiana bark Anti-enterovirus 71 activities of Melissa officinalis extract and its biologically active constituent rosmarinic acid. Sci Rep Melissa officinalis oil affects infectivity of enveloped herpesviruses Screening of antidengue activity in methanolic extracts of medicinal plants A polysaccharide fraction from medicinal herb Prunella vulgaris downregulates the expression of herpes simplex virus antigen in Vero cells Inhibition of lentivirus replication by aqueous extracts of Prunella vulgaris Structural characterization and antiviral effect of a novel polysaccharide PSP-2B from Prunellae Spica Inhibition of DNA virus: Herpes-1 (HSV-1) in cellular culture replication, through an antioxidant treatment extracted from rosemary spice Baicalin from Scutellaria baicalensis blocks respiratory syncytial virus (RSV) infection and reduces inflammatory cell infiltration and lung injury in mice Antiviral activity of polysaccharide extract from Laminaria japonica against respiratory syncytial virus Antiviral activity of ethanol extracts of Ficus binjamina and Lilium candidum in vitro Bioactive constituents of Lindernia crustacea and its anti-EBV effect via Rta expression inhibition in the viral lytic cycle Strychnos pseudoquina A. St. Hil.: a Brazilian medicinal plant with promising in vitro antiherpes activity Study on antiviral activities, drug-likeness and molecular docking of bioactive compounds of Punica granatum L. to Herpes simplex virus -2 (HSV-2) Pomegranate (Punica granatum) purified polyphenol extract inhibits influenza virus and has a synergistic effect with oseltamivir Honokiol, a Lignan biphenol derived from the magnolia tree, inhibits Dengue virus type 2 infection High antiviral effects of hibiscus tea extract on the H5 subtypes of low and highly pathogenic avian influenza viruses Cissampelos pareira Linn: Natural source of potent antiviral activity against all four Dengue virus serotypes Potent antiviral flavone glycosides from Ficus benjamina leaves In vitro cytotoxic and antiviral activities of Ficus carica latex extracts Ficus religiosa L. bark extracts inhibit infection by herpes simplex virus type 2 in vitro Ficus septica plant extracts for treating Dengue virus in vitro Antifungal activity and phytochemical analysis of Ficus sycomorus leaf extract on malassezia glubosa Syzygium aromaticum L. (myrtaceae): traditional uses, bioactive chemical constituents, pharmacological and toxicological activities Anti HSV-2 activity of Peganum harmala (L.) and isolation of the active compound Anti-Influenza virus activity and constituents characterization of Paeonia delavayi extracts Characterization of the anti-influenza activity of the Chinese herbal plant Paeonia lactiflora Geranylated flavonoids displaying SARS-CoV papain-like protease inhibition from the fruits of Paulownia tomentosa Anti-hepatitis B virus norbisabolane sesquiterpenoids from Phyllanthus acidus and the establishment of their absolute configurations using theoretical calculations Inhibition of hepatitis C virus replication by herbal extract: Phyllanthus amarus as potent natural source Evaluation of antiviral activities of four local Malaysian phyllanthus species against herpes simplex viruses and possible antiviral target Potent anti-HIV activities and mechanisms of action of a pine cone extract from Pinus yunnanensis Limonium sinense and gallic acid suppress hepatitis C virus infection by blocking early viral entry Assessment of Anti-Influenza activity and hemagglutination inhibition of Plumbago indica and Allium sativum extracts The effect of Emodin, an anthraquinone derivative extracted from the roots of Rheum tanguticum, against herpes simplex virus in vitro and in vivo Antiviral activity and constituent of Ardisia Chinensis Benth against coxsackie B3 virus Antiviral activity of Embelia ribes Burm. f. against influenza virus in vitro Methanolic extract of rhizoma coptidis inhibits the early viral entry steps of hepatitis C virus infection Medicinal herb extracts ameliorate impaired growth performance and intestinal lesion of newborn piglets challenged with the virulent porcine epidemic diarrhea virus Broad-spectrum antiviral effect of Agrimonia pilosa extract on influenza viruses Almond skin extracts abrogate HSV-1 replication by blocking virus binding to the cell Antiviral activity of extracts from Morinda citrifolia leaves and chlorophyll catabolites, pheophorbide a and pyropheophorbide a, against hepatitis C virus Antidengue potential of leaf extracts of Pavetta tomentosa and Tarenna asiatica (Rubiaceae) against dengue virus and its vector Aedes aegypti (Diptera: Culicidae) Studies on the antidiarrhoeal activity of Aegle marmelos unripe fruit : validating its traditional usage Anti-hepatitis C virus activity of a crude extract from longan (Dimocarpus longan Lour.) leaves Manassantin B shows antiviral activity against coxsackievirus B3 infection by activation of the STING/TBK-1/IRF3 signalling pathway Illicium verum: a review on its botany, traditional use, chemistry and pharmacology Ehrenb) bunge: a review of phytochemistry and pharmacology Biflavonoids from Torreya nucifera displaying SARS-CoV 3CL pro inhibition Preventive effects of a major component of green tea, Epigallocathechin-3-Gallate, on Hepatitis-B virus DNA replication Green tea extract and its major component epigallocatechin gallate inhibits hepatitis B virus in vitro Anti-hepatitis B virus activities of friedelolactones from Viola diffusa Ging In vitro inhibitory activity of Alpinia katsumadai extracts against influenza virus infection and hemagglutination Investigation into SARS-CoV-2 resistance of compounds in garlic essential oil Phenolic phytochemical displaying SARS-CoV papain-like protease inhibition from the seeds of Psoralea corylifolia Identification of natural compounds with antiviral activities against SARS-associated coronavirus Anthemis hyalina (Ah) and Citrus sinensis (Cs) extracts on the replication of coronavirus and the expression of TRP genes family SARS-CoV 3CL pro inhibitory effects of quinone-methide triterpenes from Tripterygium regelii Phytochemical analysis and in vitro antiviral activities of the essential oils of seven Lebanon species Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods Traditional Chinese medicine herbal extracts of Cibotium barometz, Gentiana scabra, Dioscorea batatas, Cassia tora, and Taxillus chinensis inhibit SARS-CoV replication Procyanidins and butanol extract of Cinnamomi Cortex inhibit SARS-CoV infection Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction Anti-SARS coronavirus 3C-like protease effects of Rheum palmatum L. extracts Targeting coronaviral replication and cellular JAK2 mediated dominant NF-κB activation for comprehensive and ultimate inhibition of coronaviral activity Novel Coronavirus during the early outbreak period: epidemiology, causes, clinical manifestation and diagnosis, prevention and control Epidemiology of seasonal coronaviruses: establishing the context for the emergence of Coronavirus disease 2019 The SARS-CoV-2 outbreak: what we know Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia Importation and human-to-human transmission of a novel Coronavirus in Vietnam COVID-19 in Brazil Drug design targeting the main protease, the Achilles Heel of coronaviruses Genotype and phenotype of COVID-19: their roles in pathogenesis Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV The spike glycoprotein of the new coronavirus 2019-nCoV contains a furinlike cleavage site absent in CoV of the same clade Highlight of immune pathogenic response and hematopathologic effect in SARS-CoV, MERS-CoV and SARS-Cov-2 infection Overview of lethal human coronaviruses Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2 Systematic comparison of two animal-to-human transmitted human Coronaviruses: SARS-CoV-2 and SARS-CoV Drug targets for corona virus: a systematic review SARS-CoV-2, SARS-CoV, and MERS-COV: a comparative overview On the origin and continuing evolution of SARS-CoV-2 Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor Recent aspects on the pathogenesis mechanism, animal models and novel therapeutics interventions for Middle East respiratory syndrome coronavirus infections COVID-19 infection: origin, transmission, and characteristics of human coronaviruses Replication and expression strategies of viruses Recent progress in the discovery of inhibitors targeting coronavirus proteases COVID-19: towards understanding of pathogenesis Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model Emerging coronaviruses: genome structure, replication, and pathogenesis The architecture of SARS-CoV-2 transcriptome COVID-19 infection: the perspectives on immune responses Clinical features of patients infected with 2019 novel coronavirus in Wuhan The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak ACE2 receptor polymorphism: susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants Structural basis of receptor recognition by SARS-CoV-2 From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design Structure of coronavirus hemagglutinin-esterase offers insight into corona and influenza virus evolution Detection of SARS-CoV-2 in different types of clinical specimens Current insight into the novel coronavirus disease 2019 (COVID-19). Nat Public Health Emerg Collect Research and development on therapeutic agents and vaccines for covid-19 and related human coronavirus diseases Coronaviruses: a paradigm of new emerging zoonotic diseases Can we contain the COVID-19 outbreak with the same measures as for SARS? Therapeutic options for the 2019 novel coronavirus (2019-nCoV) Discovery and development of safe-in-man broad-spectrum antiviral agents Antiviral activity of Illicium verum Hook. f. extracts against grouper iridovirus infection The antiviral and the coronavirus-host protein pathways inhibiting properties of herbs and natural compounds -additional weapons in the fight against the COVID-19 pandemic? Convalescent plasma as a potential therapy for COVID-19 COVID-19: immunopathology and its implications for therapy Enhancement of curcumin bioavailability by encapsulation in Sophorolipid-coated nanoparticles: an in vitro and in vivo study Arbidol: a potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2 via integrated computational approach Favipiravir as a potential countermeasure against neglected and emerging RNA viruses Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro A trial of lopinavirritonavir in adults hospitalized with severe covid-19 Drug repurposing for coronavirus (COVID-19): in silico screening of known drugs against coronavirus 3CL hydrolase and protease enzymes Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 protease against COVID-19 Discovering drugs to treat coronavirus disease 2019 (COVID-19) In-silico homology assisted identification of inhibitors of RNA binding against 2019-nCoV N-protein (N terminal domain) Teicoplanin: an alternative drug for the treatment of COVID-19? Andrographolide as a potential inhibitor of SARS-CoV-2 main protease: an in silico approach An update on current therapeutic drugs treating COVID-19 Therapeutic development and drugs for the treatment of COVID-19 Natural products in drug discovery The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety Herbal plants and plant preparations as a remedial approach for viral diseases Evaluation of cell membrane integrity as a potential antimicrobial target for plant products Original research article DNA fragmentation induced by the glycosides and flavonoids from C. coriaria Quorum sensing inhibition and antibiofilm activity of traditional Chinese medicine Antimicrobial plant metabolites: structural diversity and mechanism of action Prevention of microbial communities: novel approaches based natural products A comprehensive review on medicinal plants as antimicrobial therapeutics: potential avenues of biocompatible drug discovery In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus In silico computational screening of Kabasura Kudineerofficial Siddha Formulation and JACOM against SARS-CoV-2 spike protein In silico molecular docking analysis targeting SARS-CoV-2 spike protein and selected herbal constituents Inhibition of multiple SARS-CoV-2 proteins by an antiviral biomolecule, seselin from Aegle marmelos deciphered using molecular docking analysis Computational approach for the design of potential spike protein binding natural compounds in SARS-CoV2 In silico analysis of active compounds from siddha herbal infusion of Ammaiyar Koondhal Kudineer (Akk) against SARS-CoV-2 spike protein and its ACE2 receptor complex In silico studies reveal potential antiviral activity of phytochemicals from medicinal plants for the treatment of COVID-19 infection Natural RNA dependent RNA polymerase inhibitors: molecular docking studies of some biologically active alkaloids of Argemone mexicana Moroccan medicinal plants as inhibitors against SARS-CoV-2 main protease: computational investigations Identification of bioactive molecules from tea plant as SARS-CoV-2 main protease inhibitors Hispidin and Lepidine E: two natural compounds and folic acid as potential inhibitors of 2019-novel coronavirus main protease (2019-nCoVMpro), molecular docking and SAR study Identification of phytochemical inhibitors against main protease of COVID-19 using molecular modeling approaches Natural products and their derivatives against coronavirus: a review of the non-clinical and pre-clinical data Nature as a treasure trove of potential anti-SARS-CoV drug leads: a structural/mechanistic rationale In silico fight against novel coronavirus by finding chromone derivatives as inhibitor of coronavirus main proteases enzyme Identification of new anti-nCoV drug chemical compounds from Indian spices exploiting SARS-CoV-2 main protease as target Leucoefdin a potential inhibitor against SARS CoV-2 M In-silico approaches to detect inhibitors of the human severe acute respiratory syndrome coronavirus envelope protein ion channel Discovery of potential multi-target-directed ligands by targeting hostspecific SARS-CoV-2 structurally conserved main protease In silico screening of natural compounds against COVID-19 by targeting Mpro and ACE2 using molecular docking Virtual screening of immunomodulatory medicinal compounds as promising anti-SARS-COV-2 inhibitors Stilbene-based natural compounds as promising drug candidates against COVID-19 In silico study the inhibition of angiotensin converting enzyme 2 receptor of COVID-19 by Ammoides verticillata components harvested from Western Algeria Computational investigation on Andrographis paniculata phytochemicals to evaluate their potency against SARS-CoV-2 in comparison to known antiviral compounds in drug trials Potential inhibitors of coronavirus 3-chymotrypsin-like protease (3CL pro ): an in silico screening of alkaloids and Terpenoids from African medicinal plants Molecular docking analysis of selected natural products from plants for inhibition of SARS-CoV-2 main protease Withanone and withaferin-A are predicted to interact with transmembrane protease serine 2 (TMPRSS2) and block entry of SARS-CoV-2 into cells A computational prediction of SARS-CoV-2 structural protein inhibitors from Azadirachta indica (Neem) Natural products may interfere with SARS-CoV-2 attachment to the host cell Molecular docking, simulation and MM-PBSA studies of nigella sativa compounds: a computational quest to identify potential natural antiviral for COVID-19 treatment Phytochemical genomics-a new trend Drug development: lessons from nature Plant secondary metabolites modulate insect behavior-steps toward addiction? Plant secondary metabolites of antiviral properties a rich medicinal source for drug discovery: a mini review The role of natural products in modern drug discovery Diet components can suppress inflammation and reduce cancer risk Discovery and resupply of pharmacologically active plant-derived natural products: a review May polyphenols have a role against coronavirus infection? An overview of in vitro evidence Antiviral properties of the natural polyphenols delphinidin and epigallocatechin gallate against the flaviviruses West Nile virus, Zika virus, and dengue virus Evaluation of polyphenols from Broussonetia papyrifera as coronavirus protease inhibitors Design of a multiepitope-based peptide vaccine against the E protein of human COVID-19: an immunoinformatics approach Evaluation of green tea polyphenols as novel coronavirus (SARS CoV-2) main protease (Mpro) inhibitors -an in silico docking and molecular dynamics simulation study Inhibition of SARS-CoV 3CL protease by flavonoids In silico molecular dynamics docking of drugs to the inhibitory active site of SARS-CoV-2 protease and their predicted toxicology and ADME Molecular docking reveals the potential of Salvadora persica flavonoids to inhibit COVID-19 virus main protease The biological activity of natural alkaloids against herbivores, cancerous cells and pathogens Natural bisbenzylisoquinoline alkaloids-tetrandrine, fangchinoline, and cepharanthine, inhibit human coronavirus oc43 infection of mrc-5 human lung cells Potential of DNA intercalating alkaloids and other plant secondary metabolites against SARS-CoV-2 causing COVID-19 Chloroquine for the 2019 novel coronavirus SARS-CoV-2 Plants secondary metabolites: the key drivers of the pharmacological actions of medicinal plants Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus Current antivirals and novel botanical molecules interfering with herpes simplex virus infection Aloe polysaccharides inhibit Influenza A virus infection-a promising natural anti-flu drug Secondary metabolites in plants: main classes, phytochemical analysis and pharmacological activities Early Drug Discovery and Development Guidelines: for Academic Researchers, Collaborators, and Start-Up Companies. Assay Guidance Manual. Bethesda, MD: Eli Lilly & Company and the National Center for Advancing Translational Sciences ADME profiling in drug discovery and a new path paved on silica Biological potential and medical use of secondary metabolites A historical overview of natural products in drug discovery A review on antimicrobial botanicals, phytochemicals and natural resistance modifying agents from Apocynaceae family: possible therapeutic approaches against multidrug resistance in pathogenic microorganisms The role of plant metabolites in drug discovery: current challenges and future perspectives Effect of α-Glycosylation on the stability, antioxidant properties, toxicity, and neuroprotective activity of (-)-Epigallocatechin gallate Preclinical pharmacological activities of Epigallocatechin-3-gallate in signaling pathways: an update on cancer Crosstalk between endoplasmic reticulum stress and anti-viral activities: a novel therapeutic target for COVID-19 Colon targeted curcumin microspheres laden with ascorbic acid for bioavailability enhancement Screening and druggability analysis of some plant metabolites against SARS-CoV-2: an integrative computational approach Potential applications of plant biotechnology against SARS-CoV-2 Metabolomics for unknown plant metabolites Information theory tests critical predictions of plant defense theory for specialized metabolism Characterizing fruit ripening in plantain and Cavendish bananas: a proteomics approach Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2) China is promoting coronavirus treatments based on unproven traditional medicines Plant metabolite databases: from herbal medicines to modern drug discovery Open-access metabolomics databases for natural product research: present capabilities and future potential The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.Copyright © 2020 Bhuiyan, Howlader, Raihan and Hasan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.